Shares of Compass Pathways (CMPS) rallied Monday, briefly bypassing a profit-taking zone, on growing enthusiasm for the company’s psilocybin-based approach to treatment-resistant depression.
Psilocybin is the chemical ingredient found in magic mushrooms
But when paired with therapy, the company says the psychedelic experience could help rewire the brain in a way that tackles depression. Last week, Compass said the Food… Related news Here’s Why This Psychedelics Stock Just Took A Trip To A Two-Year High 5/13/2026 Compass Pathways stock jumped Wednesday after the psychedelics-tied biotech significantly boosted its cash holdings. 5/13/2026 Compass Pathways stock jumped Wednesday after the psychedelics-tied biotech significantly